RBCC Bioprinting Partner Expands Brand Awareness Campaign

  RBCC Bioprinting Partner Expands Brand Awareness Campaign

AACR Annual Meeting 2014

Business Wire

MIRAMAR BEACH, Fla. -- April 16, 2014

Rainbow Coral Corp.’s (OTCBB: RBCC) 3D bioprinting partner, Nano3D Biosciences
(n3D), has presented their groundbreaking technology at two high-profile
events in recent weeks as part of a campaign to build brand awareness around
the revolutionary BiO Assay system.

At the 53^rd Annual Meeting and ToxExpo of the Society of Toxicology in
Phoenix, n3D delivered a poster session presentation titled, “A Novel
High-Concept Assay for Drug Toxicity Screening.” The largest event of its
kind, the Society’s annual meeting brought together more than 6,000
toxicologists from more than 50 countries.

Earlier this month, n3D shared a booth at the 105th Annual Meeting of the
American Association for Cancer Research in San Diego. A premiere cancer
research event, the meeting was host to about 18,000 researchers, patient
advocates and other professionals in the cancer field from around the world.

By presenting and exhibiting at such landmark events, n3D is helping to spread
the word amongst international researchers about its incredible breakthrough
technology, the BiO Assay. The BiO Assay is the world’s first commercially
available 3D bioprinting system designed for high throughput and high-content
drug screening. The automated toxicity assay uses biocompatible magnetic
nanoparticles to print cells into 3D structures much faster and more
affordably than competing bioprinting tech currently on the market.

“These events are how the latest knowledge in the fields of toxicology and
cancer research is spread,” said RBCC CEO Kimberly Palmer. “They are important
showcases for new technologies such as the BiO Assay, and they’re only the
beginning of the international brand awareness campaign that our joint venture
has planned for 2014.”

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop
new medical and research technology innovations to compete alongside companies
such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and
Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity
interest in n3D.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visitwww.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President and CEO
info@rainbowbiosciences.com
 
Press spacebar to pause and continue. Press esc to stop.